secwatch.observer — SEC 8-K summary
======================================

Issuer:     AIM ImmunoTech Inc. (AIM)
CIK:        0000946644
Form:       8-K
Filed at:   2026-08-06T21:22:52+00:00
Accession:  0001493152-26-036408
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 5.08, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AIM ImmunoTech enters $1.5M manufacturing agreement with Sterling Pharma for Ampligen drug substance
--------------------------------------------------------------------------------

- Agreement with Sterling Pharma Solutions to manufacture PolyI and Poly C12U (precursors to Ampligen) at Dudley, UK site.
- Estimated cost ~$1.5M over 12 months; includes process development, non-GMP demo batches, analytical method validation, and one cGMP batch each.
- Product intended for ongoing and future clinical trials, including potential Phase 3 for metastatic pancreatic cancer.
- Shareholder director nominations for 2026 annual meeting must be received between Aug 18 and Sep 17, 2026; universal proxy deadline Oct 19, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946644/000149315226036408/0001493152-26-036408-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946644/000149315226036408/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-036408

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer